Study Stopped
No participants enrolled
Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
Immunomodulation Analysis on Peripheral Blood Mononuclear Cells of Radiation Therapy in Pediatric Malignant Brain Tumors
1 other identifier
observational
N/A
1 country
1
Brief Summary
To investigate the effect of radiotherapy on peripheral blood immune cell composition and function in pediatric malignant brain tumor patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Feb 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2019
CompletedFirst Submitted
Initial submission to the registry
July 11, 2019
CompletedFirst Posted
Study publicly available on registry
July 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2022
CompletedFebruary 7, 2024
February 1, 2024
3.2 years
July 11, 2019
February 5, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
The changes of peripheral blood immune cells
The flow cytometric analysis of lymphocyte subtypes populations would be performed
6 weeks (prior and post the radiation therapy )
Secondary Outcomes (2)
Activation status of T cells
6 weeks (prior and post the radiation therapy )
The changs of inflammatory cytokines and chemokines
6 weeks (prior and post the radiation therapy )
Eligibility Criteria
The brain tumors patients between the ages of 3 year and 18 years who will be received radiation therapy evaluated and determined by their physician
You may qualify if:
- Age from 3 to 18
- To be diagnosed with malignant brain tumors
- To eligible for radiation therapy
- Karnofsky performance status ≥ 70
- No prior radiation exposure
- Informed consent signed for blood sample collection and used for research purpose
You may not qualify if:
- Patients had received radiotherapy previously.
- Patients who had no histological diagnosis
- Patients who do not wish to participate
- Patients with infections
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Shijitan Hospital Cancer Center
Beijing, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Cancer Center Director
Study Record Dates
First Submitted
July 11, 2019
First Posted
July 15, 2019
Study Start
February 1, 2019
Primary Completion
May 1, 2022
Study Completion
May 31, 2022
Last Updated
February 7, 2024
Record last verified: 2024-02